|
| 1 |
|
Conditions listed in this trial |
|
|
Endometrial Cancer |
|
| 2 |
|
Additional conditions recognized in this trial |
|
|
Colonic Neoplasms |
|
|
Colorectal Neoplasms, Hereditary Nonpolyposis |
|
|
Endometrial Neoplasms |
|
| 3 |
|
More general conditions related to this trial |
|
|
Colonic Diseases |
|
|
Colorectal Neoplasms |
|
|
Digestive System Diseases |
|
|
Digestive System Neoplasms |
|
|
DNA Repair-Deficiency Disorders |
|
|
Gastrointestinal Diseases |
|
|
Gastrointestinal Neoplasms |
|
|
Genetic Diseases, Inborn |
|
|
Genital Diseases, Female |
|
|
Genital Neoplasms, Female |
|
|
Intestinal Diseases |
|
|
Intestinal Neoplasms |
|
|
Metabolic Diseases |
|
|
Neoplasms |
|
|
Neoplasms by Site |
|
|
Neoplastic Syndromes, Hereditary |
|
|
Urogenital Neoplasms |
|
|
Uterine Diseases |
|
|
Uterine Neoplasms |
|
| 4 |
|
Interventions listed in this trial |
|
|
ethinyl estradiol |
|
|
medroxyprogesterone |
|
|
norgestrel |
|
| 5 |
|
Additional drug interventions recognized in this trial |
|
|
Medroxyprogesterone 17-Acetate |
|
| 6 |
|
More general drug interventions related to this trial |
|
|
Antineoplastic Agents |
|
|
Antineoplastic Agents, Hormonal |
|
|
Contraceptive Agents |
|
|
Contraceptive Agents, Female |
|
|
Contraceptive Agents, Male |
|
|
Contraceptives, Oral |
|
|
Contraceptives, Oral, Synthetic |
|
|
Estrogens |
|
|
Hormones |
|
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
|
Pharmacologic Actions |
|
|
Physiological Effects of Drugs |
|
|
Reproductive Control Agents |
|
|
Therapeutic Uses |
|
| 7 |
|
Sponsors listed in this trial |
|
|
M.D. Anderson Cancer Center |
|
|
National Cancer Institute (NCI) |
